Sign inCreate account

Report workspace

Add to folder
NCT06934408RECRUITINGanonymous

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

Sponsor

Source record

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase

Source record

Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of HRS-5817.

Indication / condition

AI-normalized

Obesity

Intervention

Source record

HRS-5817 Injection, HRS-5817 Injection Placebo

Source & freshness

Source record

NCT ID

NCT06934408

Original source

ClinicalTrials.gov

Source last updated

Nov 17, 2025

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06934408

Title

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Status

RECRUITING

Phase

Phase 1

Condition raw

Obesity, Overweight

Condition normalized

Obesity, Overweight

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of HRS-5817.

Target normalized

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of HRS-5817.

Interventions

HRS-5817 Injection, HRS-5817 Injection Placebo

Public preview

Source record

Fujian Shengdi Pharmaceutical Co., Ltd. is currently conducting a Phase I clinical trial for HRS-5817, targeting obesity and overweight conditions. The trial aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult volunteers, with an estimated enrollment of 92 participants. The obesity treatment market is significant, with increasing prevalence globally, suggesting potential commercial viability for HRS-5817 if proven effective. Competitive analysis should consider existing therapies and emerging candidates in the obesity space, as well as the regulatory landscape in China and globally. Diligence implications include assessing the trial's progress, potential market entry barriers, and the company's overall pipeline.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Injections of HRS-5817 Injection in Healthy Adult Volunteers With or Without Obesity

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT06934408

Status

RECRUITING

Phase

Phase 1

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

Fujian Shengdi Pharmaceutical Co., Ltd. is currently conducting a Phase I clinical trial for HRS-5817, targeting obesity and overweight conditions. The trial aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult volunteers, with an estimated enrollment of 92 participants. The obesity treatment market is significant, with increasing prevalence globally, suggesting potential commercial viability for HRS-5817 if proven effective. Competitive analysis should consider existing therapies and emerging candidates in the obesity space, as well as the regulatory landscape in China and globally. Diligence implications include assessing the trial's progress, potential market entry barriers, and the company's overall pipeline.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 17, 2025
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06934408

Indication

Obesity

Modality

small molecule

Target

Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of HRS-5817.

Intervention

HRS-5817 Injection, HRS-5817 Injection Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.